Toronto, Ontario–(Newsfile Corp. – February 19, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-based index provider, Solactive (the “Index“).

The Index is designed to provide a measure of the performance of North American publicly listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. The Index is passive, weighing constituent companies according to their market cap, with a number of conditions that prevent the Index becoming dominated by big pharma, and by psychedelics companies with the largest market cap. Additionally, certain index funds, including the Horizons Psychedelic Stock Index ETF, utilize the Index as a benchmark.

James Lanthier, CEO of Mindset commented, “Investor interest in the potential therapeutic benefit of psychedelic drugs is increasing rapidly and we are pleased to have been added to Solactive’s North American Psychedelics Index. This is significant recognition for Mindset as it reflects our position as a progressive and highly innovative company in the psychedelic space. We believe our addition into the Index will lead to increased exposure and improved liquidity for the Company as we continue to develop our novel next-generation psychedelic drug candidates as well as our patent-pending scalable, cost effective psilocybin synthesis process.”

Additionally, the Company will be hosting an investor conference call and webcast on Monday February 22, 2021 at 2:00 p.m. EST with James Lanthier, Chief Executive Officer and Joseph Araujo, Chief Science Officer to discuss updates on the Company’s scientific programs.

Investors can access the live conference call and webcast by clicking on the event link http://services.choruscall.ca/links/mindsetpharma20210222.html or can dial in using the numbers below.

PARTICIPANT TELEPHONE NUMBERS

Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 minutes prior to the scheduled start time and simply ask to join your call.

FOR MORE INFORMATION, PLEASE CONTACT:

James Lanthier
Chief Executive Officer
[email protected]

Jason Atkinson
VP, Corporate Development
[email protected]

About Mindset Pharma Inc.

Mindset is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74921